We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Treating Dementia: Sodium Selenate Shows Promise in Phase 1 Study
News

Treating Dementia: Sodium Selenate Shows Promise in Phase 1 Study

Treating Dementia: Sodium Selenate Shows Promise in Phase 1 Study
News

Treating Dementia: Sodium Selenate Shows Promise in Phase 1 Study

Credit: Raman Oz/ Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Treating Dementia: Sodium Selenate Shows Promise in Phase 1 Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A Monash University led study has found a promising new treatment for patients with behavioural variant frontotemporal dementia, the second most common form of dementia in the under 60s – resulting in a stabilising of what would normally be escalating behavioural issues, and a slowing of brain shrinkage due to the disease. It is the second clinical trial to show that the drug, sodium selenate, may slow cognitive decline and neurodegenerative damage that is the hallmark of many dementias including Alzheimer’s Disease.


Behavioural variant frontotemporal dementia (bvFTD) is a rapidly progressing destructive disease and can occur in people as young as 35 years of age. It is characterised by behavioural disturbances and personality changes and can be highly disruptive and distressing for both patients and their families. Currently there are no treatments or cures for bvFTD and typical survival is 5-7 years from diagnosis.


The Phase 1 trial run in conjunction with the Royal Melbourne Hospital, the only one in Australia targeting non-genetic bvFTD, and one of a handful worldwide, showed that the drug, sodium selenate is safe and well-tolerated in patients with bvFTD over a period of 12 months.  Importantly, the majority of patients receiving sodium selenate showed no change in their cognitive or behavioural symptoms, and reduced rates of brain atrophy over the trial period. The results from the trial, led by Dr Lucy Vivash, from the Monash University’s Department of Neuroscience, have just been published in the journal, Alzheimer’s and Dementia: Translational Research and Clinical Interventions.


In almost half of the cases with bvFTD, the damage to the neurons in the brain is caused by the build-up of a protein called tau. This protein is a major target for research in the prevention and treatment of Alzheimer’s and other dementias, as a way to reverse the neurodegeneration caused by this tau accumulation.


According to Dr Vivash, sodium selenate upregulates an enzyme in the brain that effectively breaks down the tau protein. “We have previously shown, in a Phase 2 trial, that sodium selenate given to patients with mild to moderate Alzheimer’s Disease resulted in less neurodegeneration than in those who did not,” she said. Importantly those patients in the trial with higher levels of selenium, a breakdown product of sodium selenate, in their bloodstream showed less cognitive decline.


The research group is now conducting a larger study at many hospitals across Australia and New Zealand to further test whether this drug is beneficial for patients with bvFTD. For more information please contact selenate@alfred.org.au


Reference: Vivash L, Malpas CB, Meletis C, et al. A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer Dement.: Transl Res Clin Interven. 2022;8(1):e12299. doi: 10.1002/trc2.12299

  

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement